SCHEMBL6328584

SCHEMBL6328584

Nc1[nH]c(=O)c(C(=O)NCC2CCN(CCc3ccc(F)cc3)CC2)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR4 Q13639 4/20 0.56
GSK3B P49841 4/20 0.44
KCNH2 Q12809 3/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
CCR3 P51677 1/20 0.43
HTR2A P28223 2/20 0.43
LMNA P02545 1/20 0.43
HTR2C P28335 1/20 0.43
HTR7 P34969 1/20 0.43
HTR6 P50406 1/20 0.43
CACNA1I Q9P0X4 1/20 0.43
F10 P00742 1/20 0.42
CDK2 P24941 1/20 0.42
CDK16 Q00536 1/20 0.42
DYRK1A Q13627 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7257605 0.96 HTR4 (0.52) HTR4GSK3BKCNH2NPC1RAB9A
SCHEMBL6329186 0.92 HTR4 (0.66) HTR4KCNH2NPC1RAB9ALMNA
SCHEMBL6327265 0.91 DRD2 (0.51) HTR4GSK3BKCNH2HTR2A
SCHEMBL7257582 0.88 HTR4 (0.61) HTR4KCNH2NPC1RAB9ALMNA
SCHEMBL6327508 0.85 HTR4 (0.47) HTR4KCNH2CACNA1I
SCHEMBL6331138 0.84 HTR4 (0.56) HTR4KCNH2LMNACACNA1I
SCHEMBL6329068 0.84 HTR4 (0.56) HTR4KCNH2CACNA1I
SCHEMBL6335673 0.84 HTR4 (0.49) HTR4KCNH2CACNA1I
SCHEMBL6331374 0.84 HTR4 (0.56) HTR4GSK3BKCNH2CACNA1I
SCHEMBL6329791 0.82 KCNH2 (0.61) HTR4KCNH2LMNACACNA1I

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6979690-B2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators PFIZER INC. (US) 2005-12-27 US claimed
US-20030207875-A1 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators PFIZER INC 2003-11-06 US claimed
WO-2003057688-A2 OXO OR OXY-PYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS PFIZER JAPAN INC. (JP) 2003-07-17 WO claimed
EP-1325921-A2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators Pfizer Inc. (US) 2003-07-09 EP claimed
US-6979690-B2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators PFIZER INC. (US) 2005-12-27 US disclosed
US-20030207875-A1 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators PFIZER INC 2003-11-06 US disclosed
WO-2003057688-A2 OXO OR OXY-PYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS PFIZER JAPAN INC. (JP) 2003-07-17 WO disclosed
EP-1325921-A2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators Pfizer Inc. (US) 2003-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207875-A1 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators HRH4, HRH2, HTR4 HTR4 3/4885GSK3B 2632/4885KCNH2 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.